Paper23583246
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics.
Bartunek J and 18 others. J Am Coll Cardiol, 2013. Cited by 387 papers, by iCite.
Cite this record
ConductScience Library. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. Papers, record 23583246. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23583246
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics.
- PubMed
- Publication types
- Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Heart Failure | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Mesenchymal Stem Cell Transplantation | Major topic |
| Ventricular Remodeling | Major topic |
| Aged | |
| Female | |
| Follow-Up Studies | |
| Graft Rejection | |
| Graft Survival | |
| Heart Function Tests | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Reference Values | |
| Risk Assessment | |
| Stroke Volume | |
| Survival Rate | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00810238 | C-Cure Clinical Trial | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 23583247 | Cardiopoietry in motion: primed mesenchymal stem cells for ischemic cardiomyopathy. | https://conductscience.org/library/papers/23583247 | PubMed |
| Comment in | 24355589 | The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). | https://conductscience.org/library/papers/24355589 | PubMed |
| Comment in | 24355591 | Reply: The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). | https://conductscience.org/library/papers/24355591 | PubMed |
| Comment in | 25403118 | Redirecting stem cell therapy. | https://conductscience.org/library/papers/25403118 | PubMed |
Cited by233
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 387 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898298 | Regenerative Cardiology: Are We Close to Myocardial Repair? | J Cardiovasc Thorac Res | 2026 | https://conductscience.org/library/papers/42898298 | PubMed |
| 41851860 | Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials. | Syst Rev | 2026 | https://conductscience.org/library/papers/41851860 | PubMed |
| 41018340 | Comparison of Conventional Therapies With Stem Cell Therapy in the Treatment of Heart Disease. | Cureus | 2025 | https://conductscience.org/library/papers/41018340 | PubMed |
| 40903743 | Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update. | Eur J Med Res | 2025 | https://conductscience.org/library/papers/40903743 | PubMed |
| 40898343 | Cardiomyocyte regeneration therapy and its effect on LVEF and scar size- a systematic review and meta-analysis. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/40898343 | PubMed |
| 40725258 | Selective MicroRNA Packaging Reveals Distinct Core Signatures in Human Mesenchymal-Stromal-Cell-Derived Extracellular Vesicles. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40725258 | PubMed |
| 40576736 | Stem Cell Therapy in Ischemic Heart Failure. | Am J Cardiovasc Drugs | 2025 | https://conductscience.org/library/papers/40576736 | PubMed |
| 40422817 | Injectable Stem Cell-Based Therapies for Myocardial Regeneration: A Review of the Literature. | J Funct Biomater | 2025 | https://conductscience.org/library/papers/40422817 | PubMed |
| 40405306 | Stem cell therapy: a revolutionary cure or a pandora's box. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/40405306 | PubMed |
| 40357434 | Current state of heart failure treatment: are mesenchymal stem cells and their exosomes a future therapy? | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40357434 | PubMed |
| 40169532 | Turner syndrome: the promise of fertility via stem cell technology. | Hormones (Athens) | 2025 | https://conductscience.org/library/papers/40169532 | PubMed |
| 39886783 | Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. | Curr Cardiol Rev | 2025 | https://conductscience.org/library/papers/39886783 | PubMed |
| 39734477 | Bibliometrics of trends in global research on the roles of stem cells in myocardial fibrosis therapy. | World J Stem Cells | 2024 | https://conductscience.org/library/papers/39734477 | PubMed |
| 39451329 | Bridging the Gap: Advances and Challenges in Heart Regeneration from In Vitro to In Vivo Applications. | Bioengineering (Basel) | 2024 | https://conductscience.org/library/papers/39451329 | PubMed |
| 39259666 | Decoded cardiopoietic cell secretome linkage to heart repair biosignature. | Stem Cells Transl Med | 2024 | https://conductscience.org/library/papers/39259666 | PubMed |
| 39183341 | Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities. | Stem Cell Res Ther | 2024 | https://conductscience.org/library/papers/39183341 | PubMed |
| 39174960 | Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart failure: a meta-analysis of randomized controlled trials. | J Transl Med | 2024 | https://conductscience.org/library/papers/39174960 | PubMed |
| 38971816 | Comparative effectiveness of mesenchymal stem cell versus bone-marrow mononuclear cell transplantation in heart failure: a meta-analysis of randomized controlled trials. | Stem Cell Res Ther | 2024 | https://conductscience.org/library/papers/38971816 | PubMed |
| 38948094 | Priming mesenchymal stem cells to develop "super stem cells". | World J Stem Cells | 2024 | https://conductscience.org/library/papers/38948094 | PubMed |
| 38832190 | Stem Cell Therapy for Myocardial Infarction and Heart Failure: A Comprehensive Systematic Review and Critical Analysis. | Cureus | 2024 | https://conductscience.org/library/papers/38832190 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23583246
GET https://conductscience.org/api/papers/v1/23583246/cited_by?page=2